Case Report: Esophageal cancer under comprehensive treatment strategy—application and clinical outcome analysis of combined immunotherapy, targeted therapy, and low-dose radiotherapy
Current evidence for the combined use of immunotherapy, low-dose chemoradiotherapy, and epidermal growth factor receptor-targeted therapy for the treatment of advanced esophageal squamous cell carcinoma is lacking. We report the case of a 73-year-old woman with squamous cell carcinoma of upper middl...
Saved in:
| Main Authors: | Yanling Yuan, Xingxi Pan, Lihua Tong, Wanming He, Wen Yang |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-03-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1510371/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Adverse drug reactions to atezolizumab in combination with bevacizumab in hepatocellular carcinoma patients: an analysis of the food and drug administration adverse event reporting system database
by: Wanming He, et al.
Published: (2025-02-01) -
FLASH radiotherapy combined with immunotherapy: From biological mechanisms to blockbuster therapeutics
by: Yu Wang, et al.
Published: (2025-01-01) -
Pushing the boundaries of radiotherapy-immunotherapy combinations: highlights from the 7th immunorad conference
by: Pierre-Antoine Laurent, et al.
Published: (2025-12-01) -
Nivolumab in combination with radiotherapy for metastatic esophageal neuroendocrine carcinoma after esophagectomy: a case report
by: Kuniyasu Takagi, et al.
Published: (2021-10-01) -
Updates on radiotherapy-immunotherapy combinations: Proceedings of 6th annual ImmunoRad conference
by: Fabiana Gregucci, et al.
Published: (2023-12-01)